AU2013352379B2 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations Download PDF

Info

Publication number
AU2013352379B2
AU2013352379B2 AU2013352379A AU2013352379A AU2013352379B2 AU 2013352379 B2 AU2013352379 B2 AU 2013352379B2 AU 2013352379 A AU2013352379 A AU 2013352379A AU 2013352379 A AU2013352379 A AU 2013352379A AU 2013352379 B2 AU2013352379 B2 AU 2013352379B2
Authority
AU
Australia
Prior art keywords
compound
inhibitor compound
combination
pharmaceutically acceptable
aeb071
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013352379A
Other languages
English (en)
Other versions
AU2013352379A1 (en
Inventor
Caroline Emery
Dale Porter
Lujian TAN
Padmaja YERRAMILLI-RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013352379A1 publication Critical patent/AU2013352379A1/en
Application granted granted Critical
Publication of AU2013352379B2 publication Critical patent/AU2013352379B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2013352379A 2012-11-29 2013-11-26 Pharmaceutical combinations Active AU2013352379B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US61/731,174 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US61/731,555 2012-11-30
US201361755520P 2013-01-23 2013-01-23
US61/755,520 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
AU2013352379A1 AU2013352379A1 (en) 2015-06-11
AU2013352379B2 true AU2013352379B2 (en) 2018-09-06

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013352379A Active AU2013352379B2 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Country Status (17)

Country Link
US (1) US9446043B2 (pt)
EP (1) EP2925366B1 (pt)
JP (1) JP6437444B2 (pt)
CN (1) CN104812415A (pt)
AU (1) AU2013352379B2 (pt)
BR (1) BR112015012497B1 (pt)
CA (1) CA2892578C (pt)
DK (1) DK2925366T3 (pt)
ES (1) ES2669248T3 (pt)
HK (1) HK1215789A1 (pt)
HU (1) HUE037618T2 (pt)
NZ (1) NZ708802A (pt)
PL (1) PL2925366T3 (pt)
RU (1) RU2674995C2 (pt)
TR (1) TR201806682T4 (pt)
UA (1) UA115250C2 (pt)
WO (1) WO2014085381A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
EP4322953A1 (en) * 2021-04-15 2024-02-21 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
DE69428025T2 (de) 1993-12-07 2002-05-29 Lilly Co Eli Proteinkinase C-Inhibitoren
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
AU1339895A (en) 1993-12-23 1995-07-10 Eli Lilly And Company Protein kinase c inhibitors
NZ323571A (en) 1995-11-20 1998-12-23 Lilly Co Eli Protein kinase c inhibitor
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AU2002221810B2 (en) 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
TWI343377B (en) * 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
RU2364596C2 (ru) 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
UA93678C2 (ru) 2005-05-18 2011-03-10 Астразенека Аб Гетероциклические ингибиторы mek и их применение
PT1904482E (pt) 2005-07-11 2011-04-01 Novartis Ag Derivados de indolilmaleimida

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Lee, PA et al (2010) Cancer Research 70: 8 Supplement: 2515-2515 *
Velho, TR et al (2012) Anticancer Research 32: 2591-2598 *
Woessner, R et al (2010) Cancer Research 70: 8 Supplement: 2514-2514 *
Wu, X et al (2012) Mol Cancer Ther 11(9): 1905–14 *
Wu, X et al (2012) PLoS ONE 7(1): e29622 *

Also Published As

Publication number Publication date
AU2013352379A1 (en) 2015-06-11
HK1215789A1 (zh) 2016-09-15
EP2925366B1 (en) 2018-02-21
US9446043B2 (en) 2016-09-20
NZ708802A (en) 2019-09-27
ES2669248T3 (es) 2018-05-24
US20150306101A1 (en) 2015-10-29
BR112015012497A2 (pt) 2017-07-11
HUE037618T2 (hu) 2018-09-28
CN104812415A (zh) 2015-07-29
RU2015124954A (ru) 2017-01-11
TR201806682T4 (tr) 2018-06-21
BR112015012497B1 (pt) 2022-05-17
PL2925366T3 (pl) 2018-08-31
BR112015012497A8 (pt) 2019-10-01
UA115250C2 (uk) 2017-10-10
CA2892578A1 (en) 2014-06-05
EP2925366A1 (en) 2015-10-07
JP2016501222A (ja) 2016-01-18
CA2892578C (en) 2021-01-12
JP6437444B2 (ja) 2018-12-12
WO2014085381A1 (en) 2014-06-05
RU2674995C2 (ru) 2018-12-14
DK2925366T3 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
US9675595B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
AU2019226212B2 (en) Combination of Pl3K inhibitor and c-Met inhibitor
WO2015097621A2 (en) Pharmaceutical combinations
US20210161888A1 (en) Composition and method of treating cancer associated with egfr mutation
US20160129003A1 (en) Pharmaceutical Combinations
AU2013352379B2 (en) Pharmaceutical combinations
AU2015342863A1 (en) Apilimod for use in the treatment of melanoma
US20160120871A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
WO2014174478A1 (en) Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2017013271A1 (en) Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)